BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 1983054)

  • 1. Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule.
    Strein K; Sponer G
    Z Kardiol; 1990; 79 Suppl 3():89-98. PubMed ID: 1983054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of multiple action compounds.
    Prichard BN; Tomlinson B
    Z Kardiol; 1989; 78 Suppl 3():1-6. PubMed ID: 2573211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new molecule with vasodilating and beta-adrenoceptor blocking properties.
    Abshagen U
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S23-32. PubMed ID: 2454364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure.
    DasGupta P; Broadhurst P; Lahiri A
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S12-6. PubMed ID: 1721973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-adrenoceptor blockade and vasodilatation in essential hypertension. Hemodynamic studies at rest and during exposure to stress.
    Eggertsen R
    Acta Med Scand Suppl; 1984; 689():1-46. PubMed ID: 6151343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of vasodilating beta-blockers on cardiac function and vascular resistance in essential hypertension.
    Lund-Johansen P
    Clin Nephrol; 1992; 38 Suppl 1():S78-86. PubMed ID: 1363538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive compounds with combined actions.
    Rahn KH
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S18-22. PubMed ID: 2454363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and clinical aspects of drug therapy in coronary heart disease: clinical aspects of therapy with beta-adrenoceptor antagonists.
    Prichard BN
    Z Kardiol; 1990; 79 Suppl 3():99-103. PubMed ID: 1983055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
    Ruffolo RR; Feuerstein GZ
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():247-56. PubMed ID: 9211017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carvedilol in ischaemic heart disease.
    Prichard BN
    Cardiology; 1993; 82 Suppl 3():34-9. PubMed ID: 8106163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
    Olsen SL; Gilbert EM; Renlund DG; Taylor DO; Yanowitz FD; Bristow MR
    J Am Coll Cardiol; 1995 May; 25(6):1225-31. PubMed ID: 7722114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
    Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
    Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of carvedilol, a compound with beta-blocking and vasodilating properties.
    Strein K; Sponer G; Müller-Beckmann B; Bartsch W
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S33-41. PubMed ID: 2454365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol.
    Wendt T; van der Does R; Schräder R; Landgraf H; Kober G
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S147-50. PubMed ID: 2454362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of carvedilol in congestive heart failure secondary to coronary artery disease.
    Das Gupta P; Broadhurst P; Raftery EB; Lahiri A
    Am J Cardiol; 1990 Nov; 66(15):1118-23. PubMed ID: 1977300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can intravenous beta-blockade predict long-term hemodynamic benefit in chronic congestive heart failure secondary to ischemic heart disease? A comparison of intravenous with oral carvedilol.
    DasGupta P; Lahiri A
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S62-7. PubMed ID: 1378153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute hemodynamic effects of the vasodilator beta blocker carvedilol in heart failure].
    Buchwald A; Unterberg C; van der Does R; Wiegand V
    Z Kardiol; 1990 Jun; 79(6):424-8. PubMed ID: 1974100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-blocking agents with vasodilating action.
    Prichard BN
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S1-4. PubMed ID: 1378133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of carvedilol on left ventricular function and arrhythmias during repeated short-time myocardial ischemia in experimental pigs.
    Höher M; Friedrich M; Sommer T; Marten A; Ehmer B; Hombach V; Hirche H
    Z Kardiol; 1989; 78 Suppl 3():7-15. PubMed ID: 2573214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.